Literature DB >> 32043780

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending.

Ariadna Ortiz Brugués1, Vincent Sibaud2, Beatrice Herbault-Barrés3, Sarah Betrian4, Iphigenie Korakis4, Caroline De Bataille5, Carlos Gomez-Roca4, Joel Epstein6, Emmanuelle Vigarios5.   

Abstract

Year:  2019        PMID： 32043780      PMCID： PMC7011671          DOI： 10.1634/theoncologist.2019-0467

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  10 in total

1.  Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.

Authors:  Sébastien Le Burel; Stéphane Champiat; Emilie Routier; Sandrine Aspeslagh; Laurence Albiges; Tali-Anne Szwebel; Jean-Marie Michot; Pascale Chretien; Xavier Mariette; Anne-Laure Voisin; Olivier Lambotte
Journal:  Ann Rheum Dis       Date:  2017-02-27       Impact factor: 19.103

2.  Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.

Authors:  Laura C Cappelli; Anna Kristina Gutierrez; Alan N Baer; Jemima Albayda; Rebecca L Manno; Uzma Haque; Evan J Lipson; Karen B Bleich; Ami A Shah; Jarushka Naidoo; Julie R Brahmer; Dung Le; Clifton O Bingham
Journal:  Ann Rheum Dis       Date:  2016-06-15       Impact factor: 19.103

3.  Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment.

Authors:  D Teyssonneau; S Cousin; A Italiano
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

Review 4.  Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.

Authors:  Emmanuelle Vigarios; Joel B Epstein; Vincent Sibaud
Journal:  Support Care Cancer       Date:  2017-02-22       Impact factor: 3.603

5.  Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.

Authors:  Blake M Warner; Alan N Baer; Evan J Lipson; Clint Allen; Christian Hinrichs; Arun Rajan; Eileen Pelayo; Margaret Beach; James L Gulley; Ravi A Madan; Josephine Feliciano; Margaret Grisius; Lauren Long; Astin Powers; David E Kleiner; Laura Cappelli; Ilias Alevizos
Journal:  Oncologist       Date:  2019-04-17

Review 6.  Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.

Authors:  J Narváez; P Juarez-López; J LLuch; J A Narváez; R Palmero; X García Del Muro; J M Nolla; E Domingo-Domenech
Journal:  Autoimmun Rev       Date:  2018-08-10       Impact factor: 9.754

7.  2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts.

Authors:  Caroline H Shiboski; Stephen C Shiboski; Raphaèle Seror; Lindsey A Criswell; Marc Labetoulle; Thomas M Lietman; Astrid Rasmussen; Hal Scofield; Claudio Vitali; Simon J Bowman; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2016-10-26       Impact factor: 19.103

8.  Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.

Authors:  C Calabrese; E Kirchner; A Kontzias; V Velcheti; L H Calabrese
Journal:  RMD Open       Date:  2017-03-20

9.  Nivolumab-induced sialadenitis.

Authors:  Saeko Takahashi; Xu Chieko; Tetsuya Sakai; Shigemichi Hirose; Morio Nakamura
Journal:  Respirol Case Rep       Date:  2018-04-15

10.  A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.

Authors:  Jaqueline Ghosn; Alex Vicino; Olivier Michielin; George Coukos; Thierry Kuntzer; Michel Obeid
Journal:  J Immunother Cancer       Date:  2018-10-22       Impact factor: 13.751
  10 in total
  8 in total

1.  In Reply.

Authors:  Blake Warner; Alan Baer
Journal:  Oncologist       Date:  2019-11-06

Review 2.  Salivary gland function, development, and regeneration.

Authors:  Alejandro M Chibly; Marit H Aure; Vaishali N Patel; Matthew P Hoffman
Journal:  Physiol Rev       Date:  2022-03-28       Impact factor: 46.500

Review 3.  Balancing Cancer Immunotherapy Efficacy and Toxicity.

Authors:  Douglas B Johnson; Baruch D Jakubovic; Vincent Sibaud; Meghan E Sise
Journal:  J Allergy Clin Immunol Pract       Date:  2020-06-26

Review 4.  Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Konstantinos Melissaropoulos; Kalliopi Klavdianou; Alexandra Filippopoulou; Fotini Kalofonou; Haralabos Kalofonos; Dimitrios Daoussis
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

5.  Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-PD-L1 Immune Checkpoint Inhibitor.

Authors:  Sarah Pringle; Bert van der Vegt; Xiaoyan Wang; Nico van Bakelen; T Jeroen N Hiltermann; Fred K L Spijkervet; Arjan Vissink; Frans G M Kroese; Hendrika Bootsma
Journal:  Front Oncol       Date:  2020-04-02       Impact factor: 6.244

6.  Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer.

Authors:  Tetsuo Higashi; Hideaki Miyamoto; Ryoji Yoshida; Yoki Furuta; Katsuya Nagaoka; Hideaki Naoe; Hisaki Naito; Hideki Nakayama; Motohiko Tanaka
Journal:  Intern Med       Date:  2020-06-23       Impact factor: 1.271

Review 7.  Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management.

Authors:  Zoe Apalla; Bernardo Rapoport; Vincent Sibaud
Journal:  Int J Womens Dermatol       Date:  2021-10-23

Review 8.  Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases.

Authors:  Yoshiaki Yura; Masakazu Hamada
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.